UK markets close in 8 hours 20 minutes

DBV Technologies S.A. (0QAJ.IL)

IOB - IOB Delayed price. Currency in EUR
Add to watchlist
4.4690-0.0720 (-1.59%)
As of 06:13PM BST. Market open.
Full screen
Previous close4.5410
Open4.4260
Bid4.3580 x 0
Ask4.5800 x 0
Day's range4.4260 - 4.5200
52-week range2.1916 - 10.3600
Volume6,953
Avg. volume9,751
Market cap423.783M
Beta (5Y monthly)2.08
PE ratio (TTM)N/A
EPS (TTM)-1.4820
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York

    Montrouge, France, June 16, 2022 DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, and Dr. Pharis Mohideen, Chief Medical Officer, will participate in a fireside chat on Thursday, June 16, 2022, at 12:00 p.m. ET at the JMP Securities Life Sciences Conference in New York. A we

  • Globe Newswire

    DBV Technologies Announces Private Placement Financing of $194 Million

    Montrouge, France, June 9, 2022 DBV Technologies Announces Private Placement Financing of $194 Million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT), a clinical-stage biopharmaceutical company, today announced an aggregate $194 million private investment in public equity (PIPE) financing (corresponding to €181 million on the basis of an exchange rate of $1.0739 = €1.00 published by the European Central Bank on June 8, 2022) from the sale of 32,855,669

  • Globe Newswire

    DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers

    Montrouge, France, June 7, 2022 DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers 67.0% of subjects treated with Viaskin Peanut 250 µg met response criteria at 12 months, compared with 33.5% of subjects in the placebo armPivotal trial met primary endpoint: lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 22.4%, exceeding the pre-specified threshold of 15%Safety results were gene